These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 20933559)
1. The effect of substance P1-7 amide on nociceptive threshold in diabetic mice. Ohsawa M; Carlsson A; Asato M; Koizumi T; Nakanishi Y; Fransson R; Sandström A; Hallberg M; Nyberg F; Kamei J Peptides; 2011 Jan; 32(1):93-8. PubMed ID: 20933559 [TBL] [Abstract][Full Text] [Related]
2. Substance P(1-7) induces antihyperalgesia in diabetic mice through a mechanism involving the naloxone-sensitive sigma receptors. Carlsson A; Ohsawa M; Hallberg M; Nyberg F; Kamei J Eur J Pharmacol; 2010 Jan; 626(2-3):250-5. PubMed ID: 19836387 [TBL] [Abstract][Full Text] [Related]
3. Possible involvement of cholinergic and opioid receptor mechanisms in fluoxetine mediated antinociception response in streptozotocin-induced diabetic mice. Anjaneyulu M; Chopra K Eur J Pharmacol; 2006 May; 538(1-3):80-4. PubMed ID: 16650402 [TBL] [Abstract][Full Text] [Related]
4. Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord. Tseng LF; Narita M; Mizoguchi H; Kawai K; Mizusuna A; Kamei J; Suzuki T; Nagase H J Pharmacol Exp Ther; 1997 Feb; 280(2):600-5. PubMed ID: 9023269 [TBL] [Abstract][Full Text] [Related]
5. [Intrathecal injection of Sar9, Met(O2)11-substance P, neurokinin-1 receptor agonist, increases nitric oxide synthase expression and nitric oxide production in the rat spinal cord]. Sun XC; Li WB; Li SQ; Li QJ; Chen XL; Ai J Sheng Li Xue Bao; 2003 Dec; 55(6):677-83. PubMed ID: 14695485 [TBL] [Abstract][Full Text] [Related]
6. Antitussive effect of (+/-) pentazocine in diabetic mice is mediated by delta-sites, but not by mu- or kappa-opioid receptors. Kamei J; Iwamoto Y; Misawa M; Nagase H; Kasuya Y Nihon Shinkei Seishin Yakurigaku Zasshi; 1994 Jun; 14(3):147-52. PubMed ID: 7941779 [TBL] [Abstract][Full Text] [Related]
7. Intrathecal substance P augments morphine-induced antinociception: possible relevance in the production of substance P N-terminal fragments. Komatsu T; Sasaki M; Sanai K; Kuwahata H; Sakurada C; Tsuzuki M; Iwata Y; Sakurada S; Sakurada T Peptides; 2009 Sep; 30(9):1689-96. PubMed ID: 19520130 [TBL] [Abstract][Full Text] [Related]
8. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. Williams J; Haller VL; Stevens DL; Welch SP Eur J Pharmacol; 2008 Apr; 584(1):78-86. PubMed ID: 18313663 [TBL] [Abstract][Full Text] [Related]
9. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. Wells JL; Bartlett JL; Ananthan S; Bilsky EJ J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048 [TBL] [Abstract][Full Text] [Related]
10. Mutual antagonism between nerve growth factor and substance P N-terminal activity on nociceptive activity in mice. Larson AA; Kitto KF J Pharmacol Exp Ther; 1997 Sep; 282(3):1345-50. PubMed ID: 9316845 [TBL] [Abstract][Full Text] [Related]
11. Peripheral antinociceptive effects of the cyclic endomorphin-1 analog c[YpwFG] in a mouse visceral pain model. Bedini A; Baiula M; Gentilucci L; Tolomelli A; De Marco R; Spampinato S Peptides; 2010 Nov; 31(11):2135-40. PubMed ID: 20713109 [TBL] [Abstract][Full Text] [Related]
12. Antinociception produced by oral, subcutaneous or intrathecal administration of SC-39566, an opioid dipeptide arylalkylamide, in the rodent. Hammond DL; Stapelfeld A; Drower EJ; Savage MA; Tam L; Mazur RH J Pharmacol Exp Ther; 1994 Feb; 268(2):607-15. PubMed ID: 8113971 [TBL] [Abstract][Full Text] [Related]
13. Role of alpha2-adrenoceptors in enhancement of antinociceptive effect in diabetic mice. Omiya Y; Yuzurihara M; Suzuki Y; Kase Y; Kono T Eur J Pharmacol; 2008 Sep; 592(1-3):62-6. PubMed ID: 18625215 [TBL] [Abstract][Full Text] [Related]
15. Effects of mexiletine on formalin-induced nociceptive responses in mice. Kamei J; Hitosugi H; Kasuya Y Res Commun Chem Pathol Pharmacol; 1993 May; 80(2):153-62. PubMed ID: 7686682 [TBL] [Abstract][Full Text] [Related]
16. N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system. Quintão NL; da Silva GF; Antonialli CS; de Campos-Buzzi F; Corrêa R; Filho VC Anesth Analg; 2010 Mar; 110(3):942-50. PubMed ID: 20185671 [TBL] [Abstract][Full Text] [Related]
17. Antinociceptive effects of the ORL1 receptor agonist nociceptin/orphanin FQ in diabetic mice. Kamei J; Ohsawa M; Kashiwazaki T; Nagase H Eur J Pharmacol; 1999 Apr; 370(2):109-16. PubMed ID: 10323258 [TBL] [Abstract][Full Text] [Related]
18. Antinociceptive effect of mexiletine in diabetic mice. Kamei J; Hitosugi H; Kawashima N; Aoki T; Ohhashi Y; Kasuya Y Res Commun Chem Pathol Pharmacol; 1992 Aug; 77(2):245-8. PubMed ID: 1279769 [TBL] [Abstract][Full Text] [Related]
19. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. Ward SJ; Takemori AE J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119 [TBL] [Abstract][Full Text] [Related]
20. Effects of diabetes on the antinociceptive effect of (+/-)pentazocine in mice. Kamei J; Iwamoto Y; Misawa M; Nagase H; Kasuya Y Res Commun Chem Pathol Pharmacol; 1994 Apr; 84(1):105-10. PubMed ID: 8042002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]